Inhibrx Biosciences stock gains institutional support as Bank of America invests

Published on 09/20/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx Biosciences stock is trading around the USD 109 mark on Nasdaq as of September 19, 2026, while Bank of America Corp DE disclosed a new USD 79.70 million stake in the company. The stock carries a Moderate Buy consensus rating with an average price target of USD 197.50 from MarketBeat data in September 2026.

INBX, US45720L1070, Illustration mit AI erstellt.

Inhibrx Biosciences stock (ISIN US45720L1070) is trading at USD 109.35 on Nasdaq as of September 19, 2026, after attracting fresh institutional interest from Bank of America Corp DE with a disclosed USD 79.70 million investment in the company in September 2026, according to MarketBeat.

Fresh institutional buying supports the shares

According to MarketBeat on September 20, 2026, Bank of America Corp DE reported a new position in Inhibrx Biosciences valued at USD 79.70 million, underlining growing institutional confidence in the biotech group.

A separate filing reported by MarketBeat on September 20, 2026, shows that Tidal Investments LLC bought 10,170 shares of Inhibrx Biosciences, adding another institutional buyer to the shareholder base.

Analyst consensus points to significant upside

Based on data cited by MarketBeat in September 2026, Inhibrx Biosciences carries an average analyst rating of Moderate Buy and an average price target of USD 197.50, suggesting roughly 80.7 percent upside versus the USD 109.35 Nasdaq price as of September 19, 2026.

The same consensus data highlighted by MarketBeat indicate that several covering analysts expect the company to advance its pipeline of biologic therapies, though the stock still reflects the risks typical of clinical-stage biotechnology, including trial outcomes and regulatory decisions.

Stock level and volatility for investors

On Nasdaq, Inhibrx Biosciences stock opened at USD 109.35 on September 19, 2026, per price data referenced in the MarketBeat filing, placing the shares well below the USD 197.50 consensus target and illustrating the discount the market currently assigns to the company versus analyst expectations.